# OnCo record nct06227117 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06227117/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06227117", "NCT06227117" ;
  schema:name "Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer"@en ;
  schema:description "A phase 2 trial of Disitamab vedotin, Toripalimab, Carboplatin and Epirubicin in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06227117/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06227117> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-07-27" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/epirubicin/> ;
  onco:companies <https://onco.cc/companies/remegen/> .